What caused the pre-market move in SKIN.SW stock today?

The pre-market jump to CHF35.70 on 13 Mar 2026 was driven by higher-than-normal volume (2,756) and momentum buying above the CHF32.00 open. No single public earnings release was listed; traders likely reacted to trading flows and biotech sector interest.

What is Meyka AI's price forecast for SKIN.SW stock?

Meyka AI's forecast model projects a base target of CHF40.50, implying a 13.45% upside from CHF35.70. Forecasts are model-based projections and not guarantees.

Is SKIN.SW stock a buy for income or growth investors?

SKIN.SW is a clinical-stage biotech with negative EPS and no dividend yield. It suits growth or speculative investors focused on clinical catalysts, not income investors seeking dividends or stable cash flow.

How should traders manage risk on SKIN.SW stock in pre-market moves?

Use defined position sizing and stop-loss orders. Watch volume confirmation and resistance at CHF37.22 and CHF40.00. Link trades to upcoming clinical or corporate news to avoid gap risk at market open.

CH Stocks

SKIN.SW Cassiopea S.p.A. SIX up 9.85% pre-market 13 Mar 2026: monitor momentum and forecast

ByHuzaifa Zahoor March 13, 2026

SKIN.SW stock leads Swiss small-cap movers in pre-market trade after a 9.85% jump to CHF35.70 on 13 Mar 2026. Volume is elevated at 2,756 shares versus a 50-day average of 1,818, a relative volume of 1.52. Traders cite stronger intraday momentum and a squeeze above the CHF32.00 open and CHF36.00 intraday high. We examine technicals, financials, sector context and a model forecast to frame short-term trades on SIX in Switzerland.